{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"88.1","upperLimit":"97.6","value":"94.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"117"}],"units":"Participants"}],"description":"Assess concordance of genomic alterations in EGFR detected in plasma (using the OncotypeSEQ Liquid Select assay) versus tumor tissue (assessed centrally using FoundationOne, or locally based on the patient's clinic) in stage IV non squamous NSCLC patients who are newly diagnosed or progressing on treatment.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with non-squamous NSCLC regardless of genomic alteration status (newly diagnosed or progressing on therapy)","id":"OG000","title":"A - NSCLC All Comers Regardless of Genomic Alteration Status"}],"paramType":"NUMBER","populationDescription":"Subjects who received EGFR mutation testing on both their tissue and plasma samples.","reportingStatus":"POSTED","timeFrame":"Time between patient tumor tissue biopsy and and blood collection, up to 8 weeks","title":"Concordance of Genomic Alterations in EGFR Detected in Plasma Versus Tumor Tissue in Stage IV Non Squamous NSCLC Patients Who Are Newly Diagnosed or Progressing on Treatment","type":"PRIMARY","unitOfMeasure":"Overall percent agreement (OPA)"}